Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary...
Business Wire·8h ago
More News
Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?
Immunome (IMNM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·29d ago
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’
Craig-Hellum’s price target of $26 represents an upside of about 165% from the stock’s closing price on Thursday.
Stocktwits·2mo ago
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
Immunome (IMNM) delivered earnings and revenue surprises of +3.85% and +62.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -18.75% and -55.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·4mo ago
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
Zacks·4mo ago
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?